Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

Dr. Alicia Morgans discussed complications associated with ADT in prostate cancer, and how men can still maintain quality of ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Matthew Siskin discussing real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) ...

The firm is hoping to show in studies that its test can identify prostate cancer patients at low risk of recurrence who can receive less aggressive therapy.

Overall, thyroid-disrupting chemicals are less investigated than estrogen or androgen disrupting compounds, thus very few studies have centered on investigating TH-related endpoints of pesticide ...

A large international study led by scientists at FIMM, University of Helsinki, shows that many of the molecular differences ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES ...